Többszörösen előkezelt, irinotecan-rezisztens kolorektális karcinómában szenvedő beteg cetuximab terápiá jának eredményei

István Sipocz, Janina Kulka, Tamás Pintér

Research output: Article


Aim: The case of a patient with heavily pretreated, irinotecan-resistant, metastatic colorectal cancer is presented by the authors, and they would like to point to the effectiveness of a new therapeutic option, cetuximab treatment. Additionally, they would like to call attention to the need of performing EGFR determination from all of the biopsy samples (primary tumor, lymph nodes and metastases) to start the treatment. A weak EGFR-positivity of the primary tumor in fact does not mean the contraindication of cetuximab treatment, since the metastases, which are usually treated, could be strongly positive. The therapeutic answer could be excellent in this case, as it occurred in our case.

Original languageHungarian
Pages (from-to)337-342
Number of pages6
JournalMagyar onkologia
Issue number4
Publication statusPublished - jan. 1 2005


ASJC Scopus subject areas

  • Medicine(all)

Cite this